Allogeneic transplant following CAR T-cell therapy for large B-cell lymphomaJoanna Zurko, Alex F. Herrera, Robert J. Soiffer et al.|Haematologica|2022Cited by 73
CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World SettingBradley D. Hunter, Manali Kamdar, Matthew A. Lunning et al.|Transplantation and Cellular Therapy|2025Cited by 3
CT-305: Optimizing Post-Chimeric Antigen Receptor (CAR) T-Cell Monitoring: Evidence Across Lisocabtagene Maraleucel (liso-cel) Pivotal Clinical Trials and Real-World ExperienceManali Kamdar, Matthew A. Lunning, Mazyar Shadman et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 1
Optimizing post–chimeric antigen receptor (CAR) T cell monitoring: Evidence across lisocabtagene maraleucel (liso-cel) pivotal clinical trials and real-world experience.M. Kamdar, Matthew A. Lunning, Mazyar Shadman et al.|Journal of Clinical Oncology|2025Cited by 0
458 | OPTIMIZING POST–CHIMERIC ANTIGEN RECEPTOR T CELL MONITORING: EVIDENCE ACROSS LISOCABTAGENE MARALEUCEL PIVOTAL CLINICAL TRIALS AND REAL‐WORLD EXPERIENCEM. Kamdar, Matthew A. Lunning, Sairah Ahmed et al.|Hematological Oncology|2025Cited by 0